CHATHAM, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company, today announced that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. On June 26, 2024, Tonix received a letter from The Nasdaq Stock Market LLC stating that because Tonix's shares had a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business ...

Tonix's live virus vaccine TNX-801 is designed to provide long-term protection from mpox and smallpox with one dose TNX-801 vaccination demonstrated efficacy in protecting animals from lethal challenge with intratracheal monkeypox Clade II mpox is now endemic in the U.S. with >30,000 cases reported since May 20221 and Clade I mpox is endemic in the Democratic Republic of the Congo2 Tonix's vaccine platform has been selected by NIH's Project NextGen for clinical testing CHATHAM, N.J., June 25, 2024 (GLOBE NE ...

"People suffering with fibromyalgia tend to struggle with daily activities, have impaired quality of life and are frequently disabled", said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. "We believe the activity of Tonmya on pain, sleep quality, fatigue cognitive dysfunction, and depression are indicative of the broad-spectrum activity of Tonmya, suggesting Tonmya treats fibromyalgia at a syndromal level. We are excited by the prospect of offering this patient population its potenti ...

The gross proceeds of the offering are $4.0 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness. Lowenstein Sandler, New York, NY, represented the Com ...

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. has successfully closed a public offering, raising gross proceeds of $4.0 million, which will be utilized for working capital, general corporate purposes, and preparation for a new drug application for its Tonmya™ product candidate targeting fibromyalgia [1][4]. Group 1: Offering Details - The public offering consisted of 1,199,448 shares of common stock priced at $1.065 per share and pre-funded warrants to purchase up to 2,568,110 shares at $1.064 each, with an exercise price of $0.001 per share [4]. - Dawson James Securities, Inc. acted as the sole placement agent for the offering [5]. - The offering was conducted under an effective shelf registration statement on Form S-3 previously filed with the SEC [6]. Group 2: Company Overview - Tonix is a fully-integrated biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) disorders, with a priority to submit a New Drug Application for Tonmya in the second half of 2024 [13]. - The company has completed two statistically significant Phase 3 studies for Tonmya, which is intended for the management of fibromyalgia [13]. - Tonix's portfolio includes other product candidates targeting acute stress reaction, cocaine intoxication, organ transplant rejection, autoimmunity, and cancer [13].

The gross proceeds of the offering will be approximately $4.0 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including the preparation of the new drug application relating to its Tonmya™ product candidate in patients with fibromyalgia, and the satisfaction of any portion of its existing indebtedness. This offering is being made pursuan ...

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. plans to offer and sell shares of its common stock or pre-funded warrants, with the offering subject to market conditions and no assurance on completion or terms [2][3]. Group 1: Offering Details - The company intends to use the net proceeds from the offering for working capital, general corporate purposes, and preparation of a new drug application for its Tonmya™ product candidate targeting fibromyalgia [3]. - Dawson James Securities, Inc. is the sole placement agent for the offering [4]. - The offering is being made under an effective shelf registration statement previously filed with the SEC [9]. Group 2: Company Overview - Tonix is a fully-integrated biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) disorders and other diseases [5]. - The company aims to submit a New Drug Application (NDA) for Tonmya™ in the second half of 2024, following two successful Phase 3 studies for fibromyalgia management [5]. - Tonix's product portfolio includes TNX-102 SL for fibromyalgia and acute stress reaction, TNX-1300 for cocaine intoxication, and TNX-1500 for organ transplant rejection and autoimmune diseases [5][6].

Core Viewpoint - Tonix Pharmaceuticals Holding Corp. plans to offer and sell shares of its common stock or pre-funded warrants, subject to market conditions, with no assurance on the completion or terms of the offering [9]. Company Overview - Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing, and commercializing therapeutics for human diseases, particularly in central nervous system (CNS) disorders [5]. - The company aims to submit a New Drug Application (NDA) for its product candidate Tonmya™ for fibromyalgia management in the second half of 2024, following two statistically significant Phase 3 studies [5][6]. - Tonix's product portfolio includes TNX-102 SL for fibromyalgia and acute stress reaction, TNX-1300 for cocaine intoxication, and TNX-1500 for organ transplant rejection and autoimmune diseases [5]. Use of Proceeds - The net proceeds from the offering will be utilized for working capital, general corporate purposes, and preparation of the new drug application for Tonmya™ [3].

Tonix Pharmaceuticals (NASDAQ:TNXP) stock is falling hard on Monday after the company's shares underwent a reverse stock split this morning. That reverse stock split saw Tonix Pharmaceuticals consolidate 32 shares of TNXP stock into a single share. The company continues to trade shares under the same ticker but now uses 890260847 as its new CUSIP number. Tonix Pharmaceuticals enacted this reverse stock split to boost the price of its shares. It did this to avoid delisting from the NASDAQ Capital Market. Pri ...

CHATHAM, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock. The reverse stock split will be effective for trading purposes as of the commencement of trading on June 10, 2024. Tonix's transfer agent, VStock Transfer LLC, which is also acting ...